铂敏感复发性卵巢癌维持治疗药物的研究进展  

Research progress of maintenance drugs for platinum-sensitive recurrent ovarian cancer

作　　者：胡晓静 张荣昌 靳双玲[1] HU Xiaojing;ZHANG Rongchang;JIN Shuangling(Changzhi Medical College,Peace Hospital Attached to Changzhi Medical College,Changzhi 046000,China)

机构地区：[1]长治医学院,山西长治046000

出　　处：《临床肿瘤学杂志》2024年第4期300-304,共5页Chinese Clinical Oncology

摘　　要：卵巢癌是一种严重威胁女性生命健康的疾病,经过规范治疗后仍有超过70%的患者复发,而复发性卵巢癌无法治愈。复发性卵巢癌的经典分类方法是根据复发时距末次含铂化疗的时间间隔,分为铂敏感、铂耐药及铂难治,其中对于铂敏感复发性卵巢癌应用维持性治疗是降低复发风险或延缓复发的重要手段。本文就目前广泛应用于铂敏感复发性卵巢癌维持治疗药物的研究进展予以综述,如抗血管生成药物、聚腺苷二磷酸聚合酶抑制剂、免疫检查点抑制剂等。Ovarian cancer is a serious disease that threatens the life and health of women.More than 70%of patients experience a relapse even after receiving standard treatment.Recurrent ovarian cancer is currently considered incurable.The classical classification of recurrent ovarian cancer is divided into platinum-sensitive,platinum-resistant and platinum-refractory based on the time interval between recurrence and the last platinum-based chemotherapy.The application of maintenance therapy for pfor platinum-sensitive recurrent ovarian cancer is an important means to reduce the risk of recurrence or delay recurrence.This review focuses on the research progress of maintenance drugs widely used for platinum-sensitive recurrent ovarian cancer,such as anti-angiogenic drugs,Poly ADP-ribose polymerase inhibitors,immune checkpoint inhibitors,etc.

关 键 词：铂敏感复发性卵巢癌 维持治疗 抗血管生成药物 聚腺苷二磷酸聚合酶抑制剂 免疫检查点抑制剂 

分 类 号：R737.31[医药卫生—肿瘤]